Living meta-analysis and evidence synthesis of therapies for COVID-19

 

• COVID 19 hospitalized
• COVID 19 all comers
• COVID-19 mild to moderate
• COVID-19 severe or critically
• COVID 19 outpatients
• COVID-19 (hospitalized or not)
• COVID-19 prophylaxis (children)
• COVID-19 prophylaxis (excluding children)
• infections other than COVID-19
• Long COVID-19
• preventing respiratory virus transmission
• secondary prevention

 

• adjuvant therapies
• anticoagulant
• anticoagulant, curative dose
• enoxaparin
• heparin at therapeutic dose
• anti-inflammatoty and immuno-therapy
• anti-inflammatory therapies
• anti GM-CSF
• mavrilimumab
• clarithromycine
• colchicine
• non-steroidal anti-inflammatory drugs
• Indomethacin
• Apilimod
• corticosteroids
• Immunostimulants drugs
• anti-PD-1 antibody
• convalescent plasma treatment
• interferon
• inhaled interferon
• IFN alpha
• pegylated interferon-α2b
• interferon / TFF2
• peginterferon
• PNB001
• neutralizing antibody
• amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)
• bevacizumab
• casirivimab/imdevimab (Ronapreve)
• regdanvimab (Regkirona- CT-P59-Celltrion)
• XAV-19
• Immunosuppressants drugs
• anakinra
• anti-interleukin-6
• tocilizumab
• fostamatinib
• janus kinase (JAK) inhibitor
• baricitinib
• ruxolitinib
• tofacitinib
• lenzilumab
• Kinase inhibitors
• imatinib
• antiandrogenic
• progesterone
• antiviral and associated therapy
• azithromycin
• azvudine
• bromhexine
• chloroquine and derivatives
• chloroquine
• hydroxychloroquine
• doxycycline
• Ensitrelvir (XOCOVA)
• favipiravir
• favipiravir plus interferon
• fluvoxamine
• hydroxychloroquine plus macrolides
• azithromycin plus hydroxychloroquine
• ivermectin
• ivermectin plus doxycycline
• leronlimab
• lopinavir/ritonavir
• lopinavir/ritonavir, ribavirin and interferon beta-1b
• nitazoxanide
• remdesivir
• sofosbuvir and ledipasvir
• umifenovir (arbidol)
• zinc
• Drugs for acid related disorders
• H2 blockers
• famotidine
• miscellaneous
• camostat mesilate
• Cannabidiol
• nitric oxide (gas Inhalation or releasing solution)
• sabizabulin
• Renin-angiotensin-system-acting agents
• discontinuation of ACEI/ARB
• Vitamins
• Vitamin D
• hight dose vitamin D
• All treatment (not recommended)

    Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS) see more...